4.5 Review

Combined kidney and hematopoeitic cell transplantation to induce mixed chimerism and tolerance

期刊

BONE MARROW TRANSPLANTATION
卷 54, 期 -, 页码 793-797

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41409-019-0603-4

关键词

-

资金

  1. National Institutes of Health [P01HL075462, R01 AI 1085024]
  2. California Institute of Regenerative Medicine [CLIN2-09439]
  3. Gilead Sciences Europe Ltd
  4. Cell Source, Inc.
  5. Chorafas Institute for Scientific Exchange of the Weizmann Institute of Science
  6. Kiadis Pharma
  7. Miltenyi Biotec
  8. Celgene
  9. Centro Servizi Congressuali
  10. Almog Diagnostic

向作者/读者索取更多资源

Based on preclinical studies, combined kidney and hematopoietic cell transplantation was performed on fully HLA matched and haplotype matched patients at the Stanford University Medical Center. The object of the studies was to induce mixed chimerism, immune tolerance, and complete immunosuppressive drug withdrawal. Tolerance, persistent mixed chimerism, and complete withdrawal was achieved in the majority of fully matched patients. Persistent mixed chimerism and partial withdrawal has been achieved in the haplotype matched patients at present.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据